IL-2联褪黑素化疗后维持治疗结肠癌的，比没有维持治疗的提高了一年生存率，部分病人维持治疗时肿瘤继续退缩。
http://www.ncbi.nlm.nih.gov/pubmed/7715908
A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Abstract
Chemotherapy with 5-fluorouracil (5-FU) and folates represents the first-line standard therapy for metastatic colorectal cancer, whereas at present there is no conventional second-time treatment. Because of its importance in generating an effective anticancer immune response, interleukin-2 (IL-2) could constitute a new promising therapy of advanced colon cancer. Generally, IL-2 may determine tumor regressions in colon cancer only when it is given at high toxic doses. Our preliminary studies have shown that the pineal hormone melatonin may amplify IL-2 activity, which becomes active also at low doses in several tumor histotypes. On the basis, we have performed a clinical trial to evaluate the impact of low-dose IL-2 plus melatonin on the survival time in metastatic colon cancer, which progressed in response to 5-FU plus folates. The study included 50 metastatic colorectal cancer patients, who did not respond or progressed after initial response to first-line chemotherapy with 5-FU and folates. Patients were randomized to receive supportive care alone or low-dose subcutaneous IL-2 (3 million IU/day for 6 days/week for 4 weeks) plus melatonin (40 mg/day orally). No spontaneous tumor regression occurred in patients receiving supportive care alone. A partial response was achieved in 3/25 patients treated with immunotherapy. Percent survival at 1 year was significantly higher in patients treated with immunotherapy than in those treated with supportive care alone (9/25 vs. 3/25, p < 0.05). This study suggests that low-dose subcutaneous IL-2 plus melatonin may be effective as a second-line therapy to induce tumor regression and to prolong percent survival at 1 year in metastatic colorectal cancer patients progressing under 5-FU and folates.
|
各位大神朋友，基因检测如图所示，靶
家里老人是肺浸润性腺癌，基因检测如图片所示，想问问大神朋友，有没有遇到类似情况，
肺腺癌脑转射波刀半年后出现失语，右
我父亲62岁，2015年确诊右肺上叶腺癌，做了达芬奇机器人右肺上叶切除手术。病理为中分
肺癌晚期重生3年，爱会让人生出血肉
作者：天喜
患癌是一种锥心经历，会让人经历疼痛，还有恐慌
我79年出生，是七零尾巴。
求助： 阿美耐药, 化疗效果不好,身体
2022年7月确诊 右肺上叶近肺门肿块 纵隔淋巴结肿大 左侧锁骨淋巴结转移
基因检测，EGFR 21号外显因子，L858R
求助，由于11月刚确诊，基因检测报告今天刚出，想问一下基因检测L858R，第一次吃药是
显身卡
